Cardiff Oncology Inc. (CRDF)
Cardiff Oncology Statistics
Share Statistics
Cardiff Oncology has 66.52M shares outstanding. The number of shares has increased by 48.89% in one year.
| Shares Outstanding | 66.52M |
| Shares Change (YoY) | 48.89% |
| Shares Change (QoQ) | 42.9% |
| Owned by Institutions (%) | 59.89% |
| Shares Floating | 59.79M |
| Failed to Deliver (FTD) Shares | 13.94K |
| FTD / Avg. Volume | 1.26% |
Short Selling Information
The latest short interest is 9.48M, so 14.25% of the outstanding shares have been sold short.
| Short Interest | 9.48M |
| Short % of Shares Out | 14.25% |
| Short % of Float | 15.15% |
| Short Ratio (days to cover) | 5.73 |
Valuation Ratios
The PE ratio is -4.55 and the forward PE ratio is -3.36. Cardiff Oncology's PEG ratio is -2.12.
| PE Ratio | -4.55 |
| Forward PE | -3.36 |
| PS Ratio | 302.78 |
| Forward PS | 1.8 |
| PB Ratio | 2.49 |
| P/FCF Ratio | -5.47 |
| PEG Ratio | -2.12 |
Enterprise Valuation
Cardiff Oncology Inc. has an Enterprise Value (EV) of 46.62M.
| EV / Earnings | -1.03 |
| EV / Sales | 68.25 |
| EV / EBITDA | -0.96 |
| EV / EBIT | -0.96 |
| EV / FCF | -1.23 |
Financial Position
The company has a current ratio of 7.08, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.08 |
| Quick Ratio | 7.08 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.8 |
| Cash Flow / Debt | -24.75 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.55% and return on capital (ROIC) is -57.59%.
| Return on Equity (ROE) | -0.55% |
| Return on Assets (ROA) | -0.47% |
| Return on Capital (ROIC) | -57.59% |
| Revenue Per Employee | $21,343.75 |
| Profits Per Employee | $-1,419,718.75 |
| Employee Count | 32 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -38.39% in the last 52 weeks. The beta is 1.73, so Cardiff Oncology's price volatility has been higher than the market average.
| Beta | 1.73 |
| 52-Week Price Change | -38.39% |
| 50-Day Moving Average | 3.98 |
| 200-Day Moving Average | 3.09 |
| Relative Strength Index (RSI) | 36.56 |
| Average Volume (20 Days) | 1.1M |
Income Statement
In the last 12 months, Cardiff Oncology had revenue of 683K and earned -45.43M in profits. Earnings per share was -0.95.
| Revenue | 683K |
| Gross Profit | 683K |
| Operating Income | -48.65M |
| Net Income | -45.43M |
| EBITDA | -48.65M |
| EBIT | -48.65M |
| Earnings Per Share (EPS) | -0.95 |
Balance Sheet
The company has 51.47M in cash and 1.52M in debt, giving a net cash position of 49.95M.
| Cash & Cash Equivalents | 51.47M |
| Total Debt | 1.52M |
| Net Cash | 49.95M |
| Retained Earnings | -384.18M |
| Total Assets | 97.19M |
| Working Capital | 81.63M |
Cash Flow
In the last 12 months, operating cash flow was -37.69M and capital expenditures -80K, giving a free cash flow of -37.77M.
| Operating Cash Flow | -37.69M |
| Capital Expenditures | -80K |
| Free Cash Flow | -37.77M |
| FCF Per Share | -0.79 |
Margins
Gross margin is 100%, with operating and profit margins of -7.12K% and -6.65K%.
| Gross Margin | 100% |
| Operating Margin | -7.12K% |
| Pretax Margin | -6.66K% |
| Profit Margin | -6.65K% |
| EBITDA Margin | -7.12K% |
| EBIT Margin | -7.12K% |
| FCF Margin | -5.53K% |
Dividends & Yields
CRDF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -28.88% |
| FCF Yield | -17.26% |
Analyst Forecast
The average price target for CRDF is $10, which is 204% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 204% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Feb 20, 2019. It was a backward split with a ratio of 1:6.
| Last Split Date | Feb 20, 2019 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | 9 |
| Piotroski F-Score | 3 |